Last updated on November 2017

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)


Brief description of study

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)

Detailed Study Description

Receive EpaNova for the treatment of high triglycerides

Clinical Study Identifier: TX9178

Contact Investigators or Research Sites near you

Start Over

Julio C. Gomez, CRC

Clinical Research of South Florida
Coral Gables, FL USA
  Connect »